Building next generation RNA
Circio’s management hosted a live webinar on Wednesday 29 November, featuring a KOL presentation by circular RNA pioneer and founder of oRNA Therapeutics, Dr. Alexander Wesselhoeft.
In the webinar Circio´s management provided a company update and review of the circVec R&D program, and Dr. Wesselhoeft provided a general perspective on circRNA biology and the market landscape.
response rate in PD-1 resistant melanoma, which is one of the best published data sets in this immunotherapy-resistant cancer type
Circio aims to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives